FDA Approves New Animal Drug for Babesiosis Treatment in Dogs

Summary

The US Food and Drug Administration (FDA) is updating its animal drug regulations to reflect the approval of a new animal drug application (NADA) submitted by Schering-Plough Animal Health Corp. for the treatment of babesiosis in dogs using the new animal drug imidocarb dipropionate solution, which can be administered via subcutaneous or intramuscular injection.